argenx Dirección

Dirección controles de criterios 3/4

El CEO de argenx's es Tim Van Hauwermeiren , nombrado en Apr 2008, tiene una permanencia de 9.75 años. compensación anual total es $11.94M, compuesta por 5.5% salario y 94.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.19% de las acciones de la empresa, por valor de $41.19M. La antigüedad media del equipo directivo y de la junta directiva es de 2.2 años y 7 años, respectivamente.

Información clave

Tim Van Hauwermeiren

Chief Executive Officer (CEO)

US$11.9m

Compensación total

Porcentaje del salario del CEO	5.5%
Permanencia del CEO	16.1yrs
Participación del CEO	0.2%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	7.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Tim Van Hauwermeiren en comparación con los beneficios de argenx?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$328m
Dec 31 2023	US$12m	US$656k	-US$295m
Sep 30 2023	n/a	n/a	-US$234m
Jun 30 2023	n/a	n/a	-US$397m
Mar 31 2023	n/a	n/a	-US$511m
Dec 31 2022	US$8m	US$639k	-US$710m
Sep 30 2022	n/a	n/a	-US$909m
Jun 30 2022	n/a	n/a	-US$907m
Mar 31 2022	n/a	n/a	-US$595m
Dec 31 2021	US$7m	US$652k	-US$408m
Sep 30 2021	n/a	n/a	-US$373m
Jun 30 2021	n/a	n/a	-US$319m
Mar 31 2021	n/a	n/a	-US$573m
Dec 31 2020	US$9m	US$641k	-US$608m
Sep 30 2020	n/a	n/a	-US$535m
Jun 30 2020	n/a	n/a	-US$359m
Mar 31 2020	n/a	n/a	-US$275m
Dec 31 2019	US$7m	US$589k	-US$181m
Sep 30 2019	n/a	n/a	-US$109m
Jun 30 2019	n/a	n/a	-US$104m
Mar 31 2019	n/a	n/a	-US$47m
Dec 31 2018	US$5m	US$573k	-US$76m
Sep 30 2018	n/a	n/a	-US$56m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$46m
Dec 31 2017	US$4m	US$365k	-US$34m

Compensación vs. Mercado: La compensación total ($USD11.94M) de Tim está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.52M).

Compensación vs. Ingresos: La compensación de Tim ha aumentado mientras la empresa no es rentable.

CEO

Tim Van Hauwermeiren (51 yo)

16.1yrs

Permanencia

US$11,944,835

Compensación

Mr. Timothy Van Hauwermeiren, also known as Tim, MSc, EMBA, has been Independent Director at iTeos Therapeutics, Inc. since June 2018. Mr. Van Hauwermeiren has general management and business development e...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy Van Hauwermeiren	CEO & Executive Director	16.1yrs	US$11.94m	0.19% $ 41.2m
Karl Gubitz	Chief Financial Officer	2.9yrs	US$4.76m	0.0050% $ 1.1m
Karen Massey	Chief Operating Officer	1.2yrs	US$7.65m	sin datos
Filip Borgions	VP & Global Head of Technical Operations	2.1yrs	sin datos	sin datos
Peter Ulrichts	Chief Scientific Officer	1.3yrs	sin datos	0.00087% $ 193.8k
Beth DelGiacco	VP and Global Head of Corporate Communications & Investor Relations	2.1yrs	sin datos	sin datos
Malini Moorthy	General Counsel	2.3yrs	sin datos	0% $ 0
Arjen Lemmen	Vice President of Corporate Development & Strategy	4.9yrs	sin datos	0.0021% $ 461.1k
Marc Schorpion	Global Head of Human Resources	5.4yrs	sin datos	sin datos
Andria Wilk	Global Head of Quality	4.3yrs	sin datos	0.00050% $ 111.4k
Luc Truyen	Chief Medical Officer	2.1yrs	sin datos	0.0027% $ 612.5k

2.3yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ARGN.F se considera experimentado (2.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Timothy Van Hauwermeiren	CEO & Executive Director	9.8yrs	US$11.94m	0.19% $ 41.2m
J. deBethizy	Independent Vice-Chairman of the Board	9yrs	US$482.23k	0.00076% $ 169.3k
Peter K. Verhaeghe	Independent Chairman of the Board	9.8yrs	US$660.33k	0.00076% $ 169.3k
Anthony Rosenberg	Independent Non-Executive Director	7.1yrs	US$476.82k	0.00076% $ 169.3k
James Daly	Independent Non-Executive Director	6yrs	US$482.23k	0.00076% $ 169.3k
Pamela M. Klein	Independent Non-Executive Director	8.1yrs	US$471.41k	0.00076% $ 169.3k
Hans de Haard	Member of Board Advisors	no data	sin datos	0.62% $ 138.6m
David Lacey	Member of Board Advisors	no data	US$622.58k	sin datos
Steve Krognes	Independent Non-Executive Director	1.3yrs	US$635.65k	0.00022% $ 49.0k
Camilla Sylvest	Independent Non-Executive Director	1.7yrs	US$365.24k	0.00038% $ 84.6k
Robert Woods	Member of Board Advisors	1.2yrs	US$656.08k	0.0056% $ 1.2m
Wim Parys	Member of Board Advisors	no data	sin datos	sin datos

7.1yrs

Permanencia media

62.5yo

Promedio de edad

Junta con experiencia: La junta directiva de ARGN.F se considera experimentada (7 años de antigüedad promedio).

argenx Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

argenx SE Appoints Ana Cespedes as Non-Executive Director to Its Board of Directors

argenx SE Announces the Retirement of Hans De Haard as Chief Scientific Officer

argenx Appoints Camilla Sylvest to Board of Directors

argenx SE, Annual General Meeting, May 10, 2022

Recent updates

argenx SE Appoints Dr. Brian L. Kotzin as Non-Executive Director to the Board of Directors

argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease

Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia

argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

argenx SE Announces Approval of VYVDURA (efgartigimod Alfa and Hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

argenx SE to Report Q3, 2024 Results on Oct 24, 2024

argenx SE Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

argenx SE Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia

argenx SE Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis

Argenx Se Announces 20 Presentations of Clinical Trial and Real-World Data from Studies of Vyvgart® and Vyvgart Hytrulo® (Vyvgart) in Neuromuscular Autoimmune Disease

Argenx Announces VYVGART (Efgartigimod Alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

argenx SE to Report Fiscal Year 2023 Results on Feb 29, 2024

Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx SE Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo Injection for Subcutaneous Use in Generalized Myasthenia Gravis

argenx SE Receives Notification of PDUFA Date Extension for SC Efgartigimod

argenx SE Announces Werner Lanthaler Will Resign as Non-Executive Director of Board and Chair of Audit and Compliance Committee

argenx SE Appoints Ana Cespedes as Non-Executive Director to Its Board of Directors

argenx SE Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review

argenx SE Announces the Retirement of Hans De Haard as Chief Scientific Officer

argenx SE to Report Q3, 2023 Results on Oct 27, 2023

argenx SE Submits Biologics License Application to U.S. Food and Drug Administration for Subcutaneous Efgartigimod for Treatment of Generalized Myasthenia Gravis

argenx Appoints Camilla Sylvest to Board of Directors

Argenx Announces European Commission Approval of VYVGART(TM) (Efgartigimod Alfa-Fcab) for the Treatment of Generalized Myasthenia Gravis

argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe

argenx SE Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

argenx SE Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART (Efgartigimod Alfa-Fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual Meeting

argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting

argenx SE, Annual General Meeting, May 10, 2022

argenx SE, Annual General Meeting, May 10, 2022

argenx SE to Report Q3, 2022 Results on Oct 27, 2022

argenx SE to Report Q4, 2021 Results on Mar 03, 2022

argenx Announces VYVGART Approval in Japan for the Treatment of Generalized Myasthenia Gravis

Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis

argenx Announces Publication of Phase 3 ADAPT Trial Results of Efgartigimod for the Treatment of Generalized Myasthenia Gravis in the Lancet Neurology

argenx SE Announces FDA Acceptance of BLA Filing for Efgartigimod for the Treatment of Generalized Myasthenia Gravis

argenx Issues Statement Concerning Efgartigimod

argenx SE Announces “GO” Decision in ADHERE Trial of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy Following Interim Analysis

argenx Announcea Interim Data from the Phase 2 Culminate Trial of cusatuzumab in Development with Cilag GmbH International

argenx SE and Zai Lab Limited Announce an Exclusive License Agreement for the Development and Commercialization of efgartigimod in Greater China, Including Mainland China, Hong Kong, Taiwan and Macau

argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience

argenx Announces Partnership with Chugai and the Clayton Foundation

argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad